Tidewater Cancer News

  • Isatuximab in Multiple Myeloma
    The addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improved PFS and overall response rate among patients with relapsed or refractory multiple myeloma, according to randomized phase 3 study results presented at ASCO Annual Meeting. Isatuximab (Sanofi) is a novel anti-CD38 monoclonal antibody with multiple modes of action for killing tumor cells, including direct… Read more: Isatuximab in Multiple Myeloma